Results 61 to 70 of about 223,656 (296)

Taking hormone replacement therapy

BMJ, 2003
Women and health professionals should make the decision jointly and review it periodically In the United Kingdom women at midlife are facing the decision whether to take hormone replacement therapy or not. The backdrop to this includes widespread discussion in the media of hormone replacement therapy, high levels of lay awareness, a medical ...
openaire   +3 more sources

Proteasomal degradation of intracellularly expressed Amblyomin‐X limits suicide gene therapy potential in melanoma cells

FEBS Open Bio, EarlyView.
This study explores the feasibility of expressing the antitumoral protein Amblyomin‐X through a suicide gene therapy approach and investigates its intracellular fate after gene delivery. Although the gene is efficiently expressed, melanoma cells rapidly degrade the Amblyomin‐X protein via proteasome activity.
Victor Dal Posolo Cinel, Carlos DeOcesano Pereira, Aline Ramos Maia Lobba, Melissa Regina Fessel, Ana Marisa Chudzinski‐Tavassi   +4 more
wiley   +1 more source

Combined 5‐aminolevulinic acid and ferric ammonium citrate treatment promotes hair follicle growth by activating dermal papilla cells

FEBS Open Bio, EarlyView.
5‐Aminolevulinic acid combined with ferric ammonium citrate (5‐ALA/FAC) stimulates dermal papilla cell activity and promotes hair follicle growth. The treatment enhances ERK and AKT signaling, increases hair‐inductive gene expression, and restores dermal papilla function suppressed by dihydrotestosterone and oxidative stress, resulting in enhanced hair
Han‐Wook Ryu, Eok‐Soo Oh, Sewoon Kim
wiley   +1 more source

Treatment of hypoparathyroidism (HypoPT): Position Statement of the Expert Group for Polish Society of Endocrinology — update 2026

Endokrynologia Polska
Hypoparathyroidism (HypoPT) remains the last “classic” endocrine deficiency hormone disorder not routinely treated with hormone replacement. In November 2023, European Medicines Agency (EMA), and in August 2024, Food and Drug Administration (FDA ...
Waldemar Misiorowski, Beata Kos-Kudła, Alicja Hubalewska-Dydejczyk, Marek Ruchała, Wojciech Zgliczyński, Arkadiusz Zygmunt, John P. Bilezikian   +6 more
doaj   +1 more source

Different effects of oral and transdermal hormone replacement therapies on Factor IX, APC resistance, t-PA, PAI and C- reactive protein - a cross-sectional population survey [PDF]

, 2001
The effects of hormone replacement therapy (HRT) on thrombosis risk, thrombotic variables, and the inflammatory marker C- reactive protein (CRP) may vary by route of administration (oral versus transdermal).
Lowe, G.D.O., McConnachie, A., O'Reilly, D.S., Rumley, A., Upton, M.N., Watt, G.C.M.   +5 more
core  

Hospital Readmission After Traumatic Brain Injury Hospitalization in Community‐Dwelling Older Adults

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To examine the risk of hospital readmission after an index hospitalization for TBI in older adults. Methods Using data from the Atherosclerosis Risk in Communities (ARIC) study, we used propensity score matching of individuals with an index TBI‐related hospitalization to individuals with (1) non‐TBI hospitalizations (primary analysis)
Rachel Thomas, Connor A. Law, Joan A. Casey, Thomas Mosley, Rebecca F. Gottesman, Ramon Diaz‐Arrastia, Holly Elser, Andrea L. C. Schneider   +7 more
wiley   +1 more source

The Controversial History of Hormone Replacement Therapy

Medicina, 2019
The history of hormone replacement therapy (HRT) started in the 1960s, with very high popularity in the 1990s. The first clinical trials on HRT and chronic postmenopausal conditions were started in the USA in the late 1990s. After the announcement of the
Angelo Cagnacci, Martina Venier
doaj   +1 more source

A 73‐Year‐Old Man With Several Years of Difficulty Climbing Stairs and Frequent Tripping

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT A 73‐year‐old man presented with progressive weakness and atrophy predominantly affecting the distal finger flexors and quadriceps muscles. Electrophysiological studies demonstrated mixed myogenic and neurogenic features. Muscle MRI showed inflammatory changes, and muscle biopsy revealed granulomatous myositis with histologic features ...
Mehmet Can Sari, Arens Taga, Sonya Ulrike Steele, Ahmet Hoke   +3 more
wiley   +1 more source

Hormone Replacement Therapy after Unilateral Adrenalectomy

Journal of Education, Health and Sport
Unilateral adrenalectomy is widely performed for the treatment of both hormonally active and inactive adrenal tumors; however, the need for postoperative hormone replacement therapy (HRT) remains controversial. This study aimed to evaluate the necessity,
R. Parfentiev, Yu. Kryzhanovskyi, V. Sliepov, V. Vododyuk, N. Parfentieva   +4 more
doaj   +1 more source

Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants

Annals of Clinical and Translational Neurology, EarlyView.
Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants. ABSTRACT Objective Return of disease activity is expected when patients discontinue disease‐modifying therapy (DMT) for multiple sclerosis (MS). Some MS DMTs are associated with higher‐than‐expected disease activity (rebound) after discontinuation.
Ralf Gold, Krzysztof W. Selmaj, Regina Berkovich, Jeffrey A. Cohen, Giancarlo Comi, Eva K. Havrdová, James K. Sheffield, Hetal Desai, Chun‐Yen Cheng, Jon V. Riolo, Andrew Thorpe, Erik DeBoer, Bruce A. C. Cree   +12 more
wiley   +1 more source